Novo Holdings Pharvaris N.V. Transaction History

Novo Holdings

$1.43 Billion
Q3 2024

A detailed history of Novo Holdings transactions in Pharvaris N.V. stock. As of the latest transaction made, Novo Holdings holds 1,725,000 shares of PHVS stock, worth $35.1 Million. This represents 2.23% of its overall portfolio holdings.

Number of Shares

1,725,000

Previous 1,725,000 -0.0%

Holding current value

$35.1 Million

Previous $32.4 Million 1.49%

% of portfolio

2.23%

Previous 2.31%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$15.67 - $24.59 $8.73 Million - $13.7 Million	556,970 Added 47.68%	1,725,000 $32.4 Million
Q1 2024 May 15, 2024	SELL	$21.26 - $32.07 $7.89 Million - $11.9 Million	-371,295 Reduced 24.12%	1,168,030 $27 Million
Q4 2023 Feb 14, 2024	BUY	$15.2 - $28.05 $3.19 Million - $5.89 Million	210,000 Added 15.8%	1,539,325 $43.2 Million
Q1 2023 May 15, 2023	BUY	$6.34 - $12.27 $900,394 - $1.74 Million	142,018 Added 11.96%	1,329,325 $10.7 Million
Q4 2022 Feb 14, 2023	BUY	$1.98 - $11.46 $1.14 Million - $6.62 Million	577,307 Added 94.64%	1,187,307 $13.4 Million
Q3 2022 Nov 14, 2022	BUY	$7.67 - $25.8 $695,369 - $2.34 Million	90,661 Added 17.46%	610,000 $4.68 Million
Q2 2022 Aug 15, 2022	BUY	$16.35 - $27.5 $49,344 - $82,995	3,018 Added 0.58%	519,339 $11.5 Million
Q4 2021 Feb 14, 2022	BUY	$13.28 - $18.0 $1.29 Million - $1.75 Million	97,378 Added 23.24%	516,321 $7.43 Million
Q3 2021 Nov 15, 2021	BUY	$13.14 - $20.97 $4.04 Million - $6.45 Million	307,799 Added 276.94%	418,943 $7.43 Million
Q2 2021 Aug 16, 2021	BUY	$18.05 - $29.59 $1.1 Million - $1.81 Million	61,144 Added 122.29%	111,144 $2.07 Million
Q1 2021 May 17, 2021	BUY	$25.25 - $40.11 $1.26 Million - $2.01 Million	50,000 New	50,000 $1.4 Million

Others Institutions Holding PHVS

# of Institutions

Shares Held

39.6M

Call Options Held

Put Options Held

View Full List

About Pharvaris N.V.

Ticker PHVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 33,766,000
Market Cap $687M
Description
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, r...

More about PHVS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Novo Holdings, based on Form 13F filings with the SEC.

News

Stay updated on Novo Holdings with notifications on news.

Account